Structure of Patients with Hepatocellular Cancer (Data Analysis from Two Specialised Centres) by M. V. Mayevskaya, M. S. Novruzbekov, I. M. Borovkov, D. G. Trofimova, M. S. Zharkova, V. D. Lunkov, K. N. Lutsyk, O. D. Olisov

“…The number of patients with chronic viral hepatitis (CVH) was 651, with non-alcoholic fatty liver disease (NAFLD) — 590, with alcoholic liver disease (ALD) — 66, with autoimmune liver diseases — 416, with liver cirrhosis (LC) of any etiology 407, other liver diseases — 329. …”
Get full text

A Novel Point-of-Care Prediction Model for Steatotic Liver Disease: Expected Role of Mass Screening in the Global Obesity Crisis by Jeayeon Park, Goh Eun Chung, Yoosoo Chang, So Eun Kim, Won Sohn, Seungho Ryu, Yunmi Ko, Youngsu Park, Moon Haeng Hur, Yun Bin Lee, Eun Ju Cho, Jeong-Hoon Lee, Su Jong Yu, Jung-Hwan Yoon, Yoon Jun Kim

“…Results: A total of 20,094 individuals were categorized into SLD and non-SLD groups on the basis of the presence of fatty liver disease. We developed three prediction models: SLD model 1, which included age and body mass index (BMI); SLD model 2, which included BMI and body fat per muscle mass; and SLD model 3, which included BMI and visceral fat per muscle mass. …”
Get full text

Hepatic Steatosis Aggravates Vascular Calcification via Extracellular Vesicle‐Mediated Osteochondrogenic Switch of Vascular Smooth Muscle Cells by Zhao‐Lin Zeng, Zhi‐Bo Zhao, Qing Yuan, Shi‐Qi Yang, Zhen‐Xing Wang, Zuo Wang, Shi‐Yu Zeng, An‐Qi Li, Qian Chen, Guo‐Qiang Zhu, Xin‐Hua Xiao, Guang‐Hua Luo, Hai‐Yan Luo, Jiao‐Yang Li, Xu‐Yu Zu, Hui Xie, Jiang‐Hua Liu

“…Abstract The global incidence of metabolic dysfunction‐associated fatty liver disease (MAFLD) has risen sharply. This condition is strongly associated with the risk of cardiovascular disease (CVD), but how MAFLD affects the development and progression of CVD, particularly concerning vascular calcification, remains unclear. …”
Get full text

CISD2-mediated mitochondrial dysfunction and iron redistribution contributes to ferroptosis in arsenic-induced nonalcoholic steatohepatitis by Jingyuan Zhang, Lu Wang, Yang Lu, Fei Zheng, Xiaoqian Ding, Xiaofeng Yao, Jie Bai, Ningning Wang, Guang Yang, Tianming Qiu, Xiance Sun

“…This may provide a novel means of treatment of nonalcoholic fatty liver disease triggered by environmental factors.…”
Get full text

Meteorin-like alleviates hepatic steatosis by regulating hepatic triglyceride secretion and fatty acid oxidation by Lingyu Song, Yali Huang, Lu Liu, Xuebing Chang, Laying Hu, Guifang Wang, Lifen Xu, Tian Zhang, Yuanyuan Wang, Ying Xiao, Hong Yang, Suye Ran, Qing Shi, Tuanlao Wang, Mingjun Shi, Yuxia Zhou, Bing Guo

“…Summary: Amid a rising prevalence of non-alcoholic fatty liver disease (NAFLD), there is still an unmet need to better treat it. …”
Get full text

Short-term abstinence from alcohol and changes in cardiovascular risk factors, liver function tests and cancer-related growth factors: a prospective observational study by Gautam Mehta, Rajiv Jalan, Matteo Rosselli, James Maurice, Stewart Macdonald, Alexandra Cronberg, Tanya Khera-Butler, Colin Sumpter, Safa Al-Khatib, Anjly Jain, Christos Charalambous, Amir Gander, Cynthia Ju, Talay Hakan, Roy Sherwood, Devaki Nair, Kevin P Moore

“…These data support an independent association of alcohol consumption with cancer risk, and suggest an increased risk of metabolic diseases such as type 2 diabetes and fatty liver disease.…”
Get full text

Circulating Isthmin-1 Levels and Their Relationship with Diabetes and Metabolic Diseases in Kuwaiti Adults by Eman Alshawaf, Sulaiman K. Marafie, Mohamed Abu-Farha, Ahmed N. Albatineh, Tahani Alramah, Aldana Albuhairi, Yafa Al Qassar, Reem Zinoun, Rawan Shalabi, Sarah Behbehani, Dalal Mohammed, Fahad Alajmi, Mohammed A. Abdalla, Ebaa Al-Ozairi, Mohammad Shehab, Muhammad Abdul-Ghani, Fahd Al-Mulla, Jehad Abubaker

“…Isthmin-1 (Ism1) has recently emerged as a potential marker of metabolic health and was shown in animal studies to associate with metabolic-associated fatty liver disease (MAFLD). In this study, we aimed to investigate the circulatory levels of Ism1 in individuals with obesity compared to non-obese individuals and evaluate their association with insulin resistance, MAFLD, and T2D. …”
Get full text

Slow Metabolism–Driven Amplification of Hepatic PPARγ Agonism Mediates Benzbromarone‐Induced Obesity‐Specific Liver Injury by Guanting Li, Yourong Hu, Han Zhao, Ziyu Peng, Xin Shang, Jia Zhang, Kunxin Xie, Meiwei Li, Xiaohang Zhou, Qinyao Zhou, Kai Li, Fang Zhou, Heyao Wang, Zhijian Xu, Jiali Liu, Peng Sun

“…Abstract Obesity and nonalcoholic fatty liver disease (NAFLD) are established risk factors for drug‐induced liver injury (DILI). …”
Get full text

A New CYP2E1 Inhibitor, 12-Imidazolyl-1-dodecanol, Represents a Potential Treatment for Hepatocellular Carcinoma by Torsten Diesinger, Alfred Lautwein, Sebastian Bergler, Dominik Buckert, Christian Renz, Radovan Dvorsky, Vyacheslav Buko, Siarhei Kirko, Edith Schneider, Florian Kuchenbauer, Mukesh Kumar, Cagatay Günes, Felicitas Genze, Berthold Büchele, Thomas Simmet, Martin Haslbeck, Kai Masur, Thomas Barth, Dieter Müller-Enoch, Thomas Wirth, Thomas Haehner

“…Cytochrome P450 2E1 (CYP2E1) is a key target protein in the development of alcoholic and nonalcoholic fatty liver disease (FLD). The pathophysiological correlate is the massive production of reactive oxygen species. …”
Get full text

Rules for investigation of patients with asymptomatic elevation of serum aminotransferase activity by M. V. Mayevskaya, V. T. Ivashkin, Ye. N. German

“…Screening markers and specifying diagnostic tests are necessary to diagnose correct the majority of liver diseases – viral hepatites, alcoholic (ALD) and non-alcoholic fatty liver diseases (NAFLD), autoimmune hepatitis (AIH), Wilson diseases, primary hemochromatosis etc. …”
Get full text